共查询到20条相似文献,搜索用时 15 毫秒
1.
F Schweda F C Blumberg A Schweda M Kammerl S R Holmer G A Riegger M Pfeifer B K Kr?mer 《Nephrology, dialysis, transplantation》2000,15(1):11-15
BACKGROUND: The effects of hypoxia on renin secretion and renin gene expression have been controversial. In recent studies, we have demonstrated that acute hypoxia of 6 h duration caused a marked stimulation of renin secretion and renal renin gene expression. This hypoxia-induced stimulation of the renin-angiotensin system might contribute, for example, to the progression of chronic renal failure and to the development of hypertension in the sleep-apnoea syndrome. For this reason, we were interested in the more chronic effects of hypoxia on renal renin gene expression and its possible regulation. METHODS: Male rats were exposed to chronic normobaric hypoxia (10% O(2)) for 2 and 4 weeks. Additional groups of rats were treated with an endothelin ET(A) receptor antagonist, LU135252, or a NO donor, molsidomine, respectively. Systolic blood pressure and right ventricular pressures were measured. Renal renin, endothelin-1 and endothelin-3 gene expression were quantitated using RNAase protection assays. RESULTS: During chronic hypoxia, haematocrit increased to 72+/-2%, and right ventricular pressure increased by a mean of 26 mmHg. Renal renin gene expression was halved during 4 weeks of chronic hypoxia. This decrease was reversed by endothelin receptor blockade (105 or 140% of baseline values after treatment for weeks 3-4 or 1-4). Furthermore, there was a trend of increasing renal endothelin-1 gene expression (to 173% of baseline values) after 4 weeks of hypoxia. Systolic blood pressure increased moderately during 4 weeks of chronic hypoxia from 129+/-2 to 150+/-4 mmHg. This blood pressure increase was higher in rats treated for 4 weeks with an endothelin receptor antagonist (196+/-11 mmHg). CONCLUSIONS: Chronic hypoxia (in contrast to acute hypoxia) suppresses renal renin gene expression. This inhibition presumably is mediated by endothelins. 相似文献
2.
Hiroshi Kawaguchi Motoshi Hattori Katsumi Ito 《Pediatric nephrology (Berlin, Germany)》1997,11(3):280-284
Recombinant human growth hormone (rhGH) has been widely used to improve growth in children with chronic renal failure (CRF).
However, there has been great concern that GH may aggravate renal disease and hasten the progression to end-stage renal failure.
We therefore investigated the effect of prolonged administration of rhGH at various doses on somatic growth and renal function
and structure in rats with CRF, divided into four groups based on rhGH dose (vehicle, 0.4, 2.0, and 10.0 IU/day). rhGH was
administered subcutaneously daily for 8 weeks. The mean growth was significantly greater in rats treated with high-dose rhGH
(10.0 IU) than those treated with low-dose rhGH (P = 0.0089) or vehicle (P = 0.0011). Body weight gain increased in parallel with body length (Creatinine clearance at the end of the experiment was
significantly lower in rats on high or medium-dose rhGH than those on low-dose rhGH and controls (P <0.05). The glomerular sclerosing index was greater in rats treated with higher doses of rhGH. There were significant differences
between rats treated with high-dose rhGH and controls (P = 0.0144) and also between rats on medium-dose rhGH and controls (P = 0.0065). Although there was no significant difference, rats treated with higher doses of rhGH tended to excrete more protein.
Renal insulin-like growth factor-I (IGF-I) content and circulating IGF-I and IGF-II levels did not significantly differ among
groups. We conclude that: (1) GH improves somatic growth failure in rats with CRF, but prolonged administration of GH dose-dependently
induces deterioration in renal function and structure and (2) this effect was induced neither via circulating IGF-I and IGF-II
nor by local production of IGF-I, but seems to be direct.
Received June 7, 1996; received in revised form and accepted November 19, 1996 相似文献
3.
The effects of graded doses of dobutamine on renal function were studied in eight male volunteers. The infusion rates were 2.5, 5 and 10 micrograms/kg/min. Systolic blood pressure increased by 19% (P less than 0.01), 31% (P less than 0.01), and 44% (P less than 0.01), respectively, while diastolic blood pressure decreased by 17% (P less than 0.02), 17% (P less than 0.02) and 25% (P less than 0.01), respectively. Heart rate increased at the highest dosage by 32% (P less than 0.01). Glomerular filtration rate (GFR) diminished at all three infusion speeds by 10% (P less than 0.02), 9% (P less than 0.05) and 14% (P less than 0.02), respectively, while renal blood flow (RBF) was unchanged. Urine flow rate (UF) decreased by 36% (P less than 0.05) and fractional free water clearance (CH2O/CIn) diminished by 37% (P less than 0.05) at the rate of 10 micrograms/kg/min. Fractional potassium excretion (CK/CIn) decreased by 34% (P less than 0.01) and 44% (P less than 0.01) at the two highest rates. Fractional sodium excretion (CNa/CIn) and fractional chloride excretion (CCl/CIn) were unchanged. Catecholamine levels were unaltered. Plasma renin activity (PRA) rose significantly (P less than 0.05) at the highest infusion rate of dobutamine. It is concluded that dobutamine influences GFR, the clinical significance of which, however, is difficult to evaluate. 相似文献
4.
Heather Maxwell Devati R. Nair R. Neil Dalton Susan P. A. Rigden Lesley Rees 《Pediatric nephrology (Berlin, Germany)》1995,9(4):458-463
In normal subjects recombinant human growth hormone (rhGH) increases glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) through the action of insulin-like growth factor-I (IGF-I). We have measured clearance of inulin and para-aminohippuric acid in 18 children with chronic renal failure (CRF) during their 1st year of rhGH treatment to look at the immediate (first 3 h), short-term (1 week) and long-term (1 year) effects of treatment. On day 1 mean (range) age was 9.1 (4.9–13.9) years, GFR 19 (9–58) and ERPF 77 (34–271) ml/min per 1.73 m2. During treatment height velocity increased from 4.5 (1.7–6.5) to 9.5 (4.8–12.7) cm/year (P<0.0001). Two children required dialysis after 0.75 years and 1 child was electively transplanted after 0.5 years. There were no other serious adverse events. GFR and ERPF were unchanged in the 3 h following rhGH. GFR remained constant on day 8, 22 (6–56) and after 1 year, 20 (9–59) ml/min per 1.73 m2. ERPF increased to 96 (33–276) ml/min per 1.73 m2 on day 8P=0.005), and remained elevated, but not significantly so, at 99 (24–428) ml/min per 1.73 m2 at 1 year. Fasting IGF-I increased from 147 (46–315) ng/ml to 291 (61–673) by day 8P<0.003), and to 341 (101–786) ng/ml at 1 year. There was no correlation between the change in IGF-I and renal function. Blood pressure, albumin excretion and dietary protein intake were unchanged by treatment. The significance of increased ERPF after 1 week of rhGH in CRF is unclear, but long-term follow-up of renal function is indicated. 相似文献
5.
6.
Aydın Ece Semra Çetinkaya Seçil Ekşioğlu Saliha Şenel Serdar Özkasap Tayfur Giniş 《Renal failure》2014,36(4):508-513
Objective: The aim of this study was to investigate the kidney growth and renal functions in children receiving recombinant human growth hormone (rhGH) treatment. Materials and methods: A total of 37 children who received rhGH for 1.5 years before the study was started and 48 healthy controls were included at first evaluation. Hormone levels were determined and kidney sizes were measured by ultrasound. Kidney functions were assessed by serum creatinine and estimated glomerular filtration rate (eGFR). After 3 years of first evaluation, 23 patients were re-assessed. Results: Kidney sizes were found to be lower in rhGH received children compared with controls at first evaluation (p?0.05). Significant positive correlations were found between anthropometric measurements and kidney length and kidney volume (p?0.05). Height was the most significant predictor of kidney volume in rhGH received children (p?0.001). After 3-years of follow-up significantly increases were found in kidney length and volume compared with the first measurements (p?0.05). Increase percentage of body height was similar to increasing percent of kidney length and liver long axis (14.2%, 11.7.1% and 7.7%, respectively, p?>?0.05). Although no abnormal renal function test results were found at first and second evaluations; rhGH received children had significantly lower eGFR, at first evaluation, compared with controls; however, renal functions significantly increased after 3 years of follow-up (p?0.05). Conclusions: In conclusion, effect rhGH treatment on kidney growth is parallel to growth in body height and other visceral organs. A 3-years rhGH treatment resulted in significant increases in renal functions. 相似文献
7.
P van Paassen D de Zeeuw G Navis P E de Jong 《Nephrology, dialysis, transplantation》2000,15(5):637-643
BACKGROUND: Remikiren is an orally active renin inhibitor with established antihypertensive efficacy. As a single dose it induces renal vasodilatation, suggesting specific renal actions. Data on the renal effects of continued treatment by renin inhibition are not available, either in subjects with normal, or in subjects with impaired renal function. METHODS: The effect of 8 days of treatment with remikiren 600 mg o.i.d. on blood pressure, renal haemodynamics, and proteinuria was studied in 14 hypertensive patients with normal or impaired renal function.The study was conducted on an ambulatory in-hospital basis and was designed in a single-blind, longitudinal order. RESULTS: Remikiren induced a significant peak fall in mean arterial pressure of 11.2+/-0.8%, with corresponding trough values of -6+/-0.8%. This fall was somewhat more pronounced in the patients with renal function impairment (-13.3 vs -9.6%; P<0.01). Glomerular filtration rate remained stable, whereas effective renal plasma flow increased from 301+/-35 to 330+/-36 ml/min/1.73 m(2) (P<0.05). Filtration fraction and renal vascular resistance fell by 10+/-2% and 15+/-2% respectively (both P<0.01). Remikiren induced a cumulated sodium loss of -82+/-22 mmol and a positive potassium balance of 49+/-9 mmol (both P<0.01). During remikiren, proteinuria fell by 27% (range -18 to -38%; P<0.01) in the patients with overt proteinuria at onset (n=6). In the remainder of the patients albuminuria fell by 20% (range -1 to -61%, P<0.05). No side-effects were observed. CONCLUSIONS: Continued treatment with remikiren induced a sustained fall in blood pressure, renal vasodilatation, negative sodium balance, and a reduction in glomerular protein leakage. These data are consistent with a renoprotective potential of renin inhibition. 相似文献
8.
Sharon Bartosh Bruce Kaiser Iraj Rezvani Martin Polinsky Seth Schulman JoAnn Palmer H. J. Baluarte 《Pediatric nephrology (Berlin, Germany)》1992,6(1):68-73
The efficacy of recombinant human growth hormone (rGH) was assessed in five pediatric allograft recipients with severe growth retardation despite successful renal transplants. rGH 0.05 mg/kg per dose was given six times weekly by subcutaneous injection to five prepubertal children (mean age 15.2±2.0 years) all of whom had bone ages less than or equal to 12 years (10.0±1.4 years), a height standard deviation score of less than –2.5 (–4.9±1.5), no evidence of catch-up growth, a calculated glomerular filtration rate (GFR) of more than 40ml/min per 1.73 m2 (51±6.8 ml/min per 1.73 m2), and stable renal function on alternate-day prednisone (16.7±2.6 mg/m2 per dose). Growth hormone profiles were abnormal in all children before treatment. rGH administration led to a significant increase in both growth rate (3.5±1.6 cm/year pre therapy, 8.5±1.4 cm/year post therapy,P<0.001) and percentage of expected growth velocity for bone age (67±31% pre therapy, 163±27% post therapy,P<0.001) with evidence of true catch-up growth. During the study period, three children had the appearance of secondary sexual characteristics, and one had premature advancement of his bone age. GFR decreased in three children, and in one rGH was discontinued due to a steady rise in serum creatinine. No significant changes were seen in serum calcium, phosphorus, cholesterol, triglycerides, glucose, or thyroid function, although a significant increase in alkaline phosphatase was found. In summary, growth-retarded pediatric renal allograft recipients may have abnormal endogenous GH production and respond favorably to rGH. The potential risk of deterioration in renal function due to rGH-induced hyperfiltration must be investigated. 相似文献
9.
S Donnay F García-Martín E Martin-Escobar G De Arriba J L Agud R Requejo 《Nephrology, dialysis, transplantation》1992,7(3):246-250
To examine the response of growth hormone (GH) to growth hormone releasing factor (GHRF) in patients on haemodialysis, we performed the acute GHRF test (50 micrograms administered intravenously as a bolus) in 10 uraemic male patients on haemodialysis and eight normal controls. Each patient was tested before and after a haemodialysis session (at 08.30 and 12.30). Controls were tested on the same time schedule. At 08.30, patients had significantly greater basal and peak GH values (2.5 +/- 0.6 and 27.8 +/- 5.5 micrograms/l) than controls (0.68 +/- and 11.5 +/- 4 micrograms/l). After the haemodialysis session, basal and peak values declined significantly (P less than 0.01) in the uraemic group (0.5 +/- 0.03 and 3.1 +/- 1.1 micrograms/l), whereas the controls did not show such a change in the 12.30 test. Basal and intratest glycaemic values were comparable both before and after haemodialysis. After dialysis test results did not change either with the use of glucose-free dialysate or with bicarbonate buffer. Uraemic patients display a greater GH response to GHRF injection than normal subjects, and this response decreases after haemodialysis. The degree of reduction has no relationship with either glycaemia or the dialysate buffer. We suggest that other GH secretion regulating factors are altered by the haemodialysis procedure. 相似文献
10.
Experimental diabetic renal growth: role of growth hormone and insulin-like growth factor-I 总被引:1,自引:1,他引:0
Muchaneta-Kubara E. C.; Sayed-Ahmed N.; Besbas N.; Zhang G.; Cope G. H.; El Nahas A. M. 《Nephrology, dialysis, transplantation》1994,9(10):1395-1401
We have compared the kidneys of two inbred strains of rats (Lewisand Lewis-Dwarf) 7 days after the induction of diabetes mellituswith streptozotocin, in order to examine the influence of aselective growth hormone (GH) deficiency on diabetic renal growthand insulin-like growth factor-I (IGF-I) content of the kidneys.Insulin-like growth factor-I was measured by radioimmunoassayand its distribution within the kidney by immunohistochemicalstaining. We detected a significant increase in both the wetweight (32.9±5.3%, P=0.0085) and dry weight (16.3±6.3%,P=0.046) of the kidneys of diabetic Lewis rats but dwarf rats,selectively deficient in GH, did not show a significant increasein either parameter. Extractable IGF-I increased within thekidneys of diabetic rats of both strains but to a lesser extentin the dwarf rats (+105±28% and +65±21% respectively,P<0.0l). In diabetic Lewis rats a positive correlation wasnoted between the severity of glycaemia and kidney IGF-I content(r=0.604, P<0.05) but no such correlation was noted in dwarfrats. Insulin-like growth factor-I immunostaining increased in diabeticrats of both strains, mainly within cells of the thick ascendinglimb of the loop of Henle including damaged and vacuolated cells.However, morphometric analysis of the staining showed that itwas significantly less widespread in the diabetic dwarf rats(P=0.026). We conclude that growth hormone deficiency bluntsexperimental diabetic renal growth and restricts the increasein the kidney IGF-I content. These findings raise further questionsconcerning the contribution of GH and IGF-I to the early stagesof experimental diabetic renal disease. 相似文献
11.
12.
Crompton CH;Australian New Zealand Paediatric Nephrology Association 《Nephrology (Carlton, Vic.)》2004,9(5):325-330
BACKGROUND: Recombinant human growth hormone (rhGH) has been used for 15 years to treat Australian children with short stature caused by chronic kidney disease. The Australia-wide growth hormone database, OZGROW, has prospectively collected data for all patients treated with rhGH. The impact of rhGH therapy on linear growth in patients with chronic renal failure (CRF) was assessed by retrospectively analysing this data. METHODS: Growth data prior to and during treatment, bone age, and pubertal data were recorded from the database. Questionnaire data provided further information on underlying renal disease, medication use, bone disease, and final height. Patients were classified according to treatment modality; conservative management of CRF, haemodialysis or peritoneal dialysis, and transplant. RESULTS: Data on 183 patients were analysed. The duration of rhGH therapy ranged from 1.2 to 10.5 years (mean 5.3 years). The height standard deviation score (Ht SDS) in each patient group at the start and end of rhGH treatment were as follows: Predialysis: -2.6 to -2.1; dialysis: -2.7 to -2.3; transplant: -3.1 to -2.8 (P = 0.0001). Thirty-nine patients achieved final adult height, with mean Ht SDS before rhGH therapy being -2.65, and at final height it was 2.3. The mean final height for the males was 161.8 cm and for the females, it was 149.5 cm. CONCLUSION: The effect of treatment with rhGH was less dramatic than reported in the literature. However, the positive benefit of rhGH therapy was apparent both in the short and long-term. Therapy with rhGH maintained a steady Ht SDS with time; without rhGH, it would be anticipated that many children would show a steady decline in Ht SDS. The maximum benefit was seen in preterminal renal failure, and early therapy (before dialysis or transplantation) is recommended before an irrecoverable loss of height potential occurs. 相似文献
13.
Waller S Ledermann S Trompeter R van't Hoff W Ridout D Rees L 《Pediatric nephrology (Berlin, Germany)》2003,18(12):1236-1241
14.
Recombinant human growth hormone in infants and young children with chronic renal insufficiency 总被引:1,自引:0,他引:1
Richard N. Fine Kenneth M. Attie Joyce Kuntze Douglas F. Brown Edward C. Kohaut 《Pediatric nephrology (Berlin, Germany)》1995,9(4):451-457
Children with chronic renal insufficiency (CRI) secondary to congenital structural abnormalities frequently have significant growth retardation by 2 years of age. In a multicenter placebo-controlled study of the use of recombinant human growth hormone (rhGH), 30 of 125 (24%) participants were<2.5 years of age at enrollment. Since the treatment arms of the study were balanced for age at randomization, data for these patients were examined for efficacy and safety. During the first 2 years of the study, approximately two-thirds of the patients (n=19) received rhGH 0.05 mg/kg per day subcutaneously and one-third (n=11) received placebo injections. At entry into the study, the mean (± SD) calculated creatinine clearance was 29.2±14.3 (range 12.0–63.7) ml/min per 1.73 m2 in the rhGH-treated group and 23.3±15.1 (range 8.0–59.4) ml/min per 1.73 m2 in the placebo-treated group. The 1st year growth rate was 14.1±2.6 cm/year for the rhGH-treated group and 9.3±1.5 cm/year in the placebo-treated group (P<0.00005). During the 2nd year of the study, the growth rate was 8.6±1.2 cm/year in the rhGH-treated group compared with 6.9±1.0 in the placebo groupP=0.025). The height standard deviation score was +2.0±0.7 for the rhGH-treated group compared with –0.2±1.1 in the placebo-treated group (P<0.00005) during the 2 years of the study. Minor adverse events occurred with similar frequency in both groups. These data suggest that rhGH is efficacious and safe in children with CRI under age 2.5 years. rhGH therapy may correct significant loss of growth at this age when used in conjunction with optimal medical management. 相似文献
15.
Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency 总被引:2,自引:2,他引:0
Hokken-Koelega A Mulder P De Jong R Lilien M Donckerwolcke R Groothof J 《Pediatric nephrology (Berlin, Germany)》2000,14(7):701-706
Several prospective trials have shown that recombinant human growth hormone (GH) accelerates growth significantly during the
first years of therapy, but the effects of long-term GH therapy with regard to long-term growth response and safety have not
yet been established. Forty-five Dutch prepubertal children [28 boys, 17 girls, mean (SD) age 7.8 (3.4) years] with chronic
renal insufficiency (CRI) and severe growth retardation started GH therapy between 1988 and 1991 within one of the randomized
Dutch trials. Long-term GH therapy, in this study a maximum of 8 years, resulted in a sustained and significant improvement
of height standard deviation score (SDS) compared with baseline values (P<0.001). The mean height SDS reached the lower end (-2 SDS) of the normal growth chart after 3 years of GH therapy. During
the following years the mean height SDS gradually increased, thereby approaching the mean target height SDS after 6 years
of GH therapy. Three factors were significantly associated with the height SDS after 4 years of GH therapy: height SDS at
the start (+) of therapy, age at the start of therapy (-), and the duration of dialysis treatment (-). Bone maturation did
not accelerate during long-term GH therapy. Children on a conservative regimen at the start of GH therapy had no accelerated
deterioration of renal function during 6 years of GH therapy. The average daily GH dose administered over the years had no
significant influence on the glomerular filtration rate after 4 years. GH therapy had no adverse effects or significant effect
on parathyroid hormone concentration, nor were there any radiological signs of renal osteodystrophy. Puberty started at a
median age, within the normal range, of 12.4 years in boys and 12.0 years in girls, respectively. Long-term GH therapy leads
to a sustained improvement in height SDS in children with growth retardation secondary to CRI, resulting in a normalization
of height in accordance with their target height SDS, without evidence of deleterious effects on renal function or bone maturation.
A GH dosage of 4 IU/m2 per day appears efficient and safe. Our long-term data show that final height will be within the normal target height range
when GH therapy is continued for many years.
Received: 25 March 1999 / Revised: 13 January 2000 / Accepted: 20 January 2000 相似文献
16.
The effects of age, height velocity over the preceding year, glomerular filtration rate (GFR) and prednisolone dose on growth response have been assessed by single and multiple linear regression analysis in 23 prepubertal children [age, mean (SD), 8.2 (2.5) years] with chronic renal failure (CRF) and 16 prepubertal children [12.1 (2.3) years] with renal transplants treated for 1 year with recombinant human growth hormone (rhGH), 30 U/m2 per week. Height velocity [mean (SD), cm/year increased from 4.7 (1.3) to 9.7 (2.1) (P<0.0001) in the CRF group and 3.1 (1.6) to 7.3 (2.8) (P<0.0001) in the transplant group. In the CRF group, there was a correlation between age and height velocity, both in the pretreatment year (r=–0.755,P<0.0001) and during treatment (r=–0.421,P=0.045). There was no correlation between pretreatment height velocity or GFR and response to rhGH. In the transplanted children height velocity during the treatment year correlated with age (r=–0.647,P=0.007), prednisolone dose (r=–0.689,P=0.003), GFR (r=0.542,P=0.030) and pretreatment height velocity (r=0.655,P=0.006). Multiple regression analysis showed prednisolone dose and age to be the most important predictors of response. 相似文献
17.
目的探讨重组人生长激素(rhGH)对化疗大鼠外周血细胞学指标的影响。方法实验分空白对照组、生理盐水组、rhGH组、化疗组和化疗+rhGH组。给药后第7天、14天、21天和28天应用血液自动分析仪检测实验各组大鼠外周血中各系细胞的变化。结果给药后第7天rhGH组网织红细胞绝对数较其他各组明显增加(P〈0.05);化疗组和化疗+rhGH组外周血液中的白细胞(WBC)、血红蛋白(Hb)和网织红细胞数较其他各组明显降低(P〈0.01),但化疗+rhGH组WBC数和网织红细胞绝对数减少程度明显低于化疗组(P〈0.05)。给药后第14天化疗组和化疗+rhGH组外周血中红细胞数(RBC)和Hb与其他各组比较明显降低(P〈0.05),但化疗+rhGH组减少程度明显低于化疗组(P〈0.05);化疗+rhGH组网织红细胞绝对数较其他各组明显增加(P〈0.05);各组间WBC比较差异无显著性(P〉0.05)。给药后第21天,化疗组RBC、Hb计数低于对照组(P〈0.05),而化疗+rhGH组WBC、RBC、Hb计数与对照组比较差异无显著性(P〉0.05),网织红细胞绝对数高于其他各组(P〈0.05)。结论rhGH对化疗大鼠的造血功能有一定的保护作用。 相似文献
18.
G. Guest E. Bérard H. Crosnier T. Chevallier R. Rappaport M. Broyer 《Pediatric nephrology (Berlin, Germany)》1998,12(6):437-446
From 1991 to 1993, 90 children having received a kidney graft with a post-transplantation period of at least 12 months were
included in a prospective study carried out in 18 French pediatric centers. After informed consent and randomization, children
received recombinant human growth hormone (rhGH) (Genotonorm, Pharmacia peptide hormones) 30 U/m2 per week, either immediately on enrollment, for the treated group, or after 1 year of follow-up for the group serving as
a control. After 1 year both groups were treated and we analyzed data during the subsequent years. Eighty-five children completed
the 1-year study. Growth velocity was significantly increased by rhGH: 7.7 cm with a gain of +0.3 standard deviation score
in the treated group versus 4.6 cm in the control group (P<0.0001) during the 1st year. Four factors predicted response to therapy: growth velocity prior to GH therapy, glomerular
filtration rate (GFR) at the start, mode of corticosteroid administration, and degree of insulin resistance. After 1 year
we observed a moderate, significant decrease in GFR in both groups. Biopsy-proven acute rejection episodes were not significantly
more frequent during the 1st year in the group of patients who received rhGH: 9 in 44 versus 4 in 46 patients. The patients
who rejected did not differ in terms of age, renal function at the start, and type of immunosuppression, but history of rejection
before GH treatment was discriminatory: 6 of 17 children with two or more episodes had a new rejection versus 1 of 22 who
had no or only one episode (P=0.01). Glucose tolerance was not modified after 1 year of GH therapy. During the subsequent years of treatment a decrease
in growth velocity was noted: 5.9 cm at 2 years, 5.5 at 3 years, and 5.2 cm at 4 years. In conclusion, GH is efficient for
improving growth velocity in short transplanted children, inducing clear-cut but limited catch-up growth. The risk of rejection
was shown only in patients with a prior history of more than one rejection episode.
Received October 3, 1997; received in revised form and accepted January 26, 1998 相似文献
19.
David R. Powell Ron G. Rosenfeld Raymond L. Hintz 《Pediatric nephrology (Berlin, Germany)》1988,2(4):425-430
We examined the effects of methionylhuman growth hormone (met-hGH) and malnutrition on the growth of 5/6 nephrectomized rats and sham-operated controls. One group of shamoperated rats (PFS) was pair-fed with a group of nephrectomized rats in renal failure (RF); another group of sham-operated rats was fed ad libitum (ALS), and a final group of rats with renal failure (RF-GH) was treated with 4 IU/day met-hGH. After 4 weeks, RF-GH rats gained 12.3±1.7 cm in length; this was more than the 10.2±1.2 cm gain of RF rats (P<0.05). Ingested food was converted into weight gain more efficiently by RF-GH rats than RF rats (267±26 vs 235±38 mg weight gain/g food intake,P<0.05). RF-GH rats also gained more weight (122±25 g) than RF rats (98±27 g), but this difference was not significant (0.05<P<0.1). Insulin-like growth factor (IGF)-I, glucose and insulin levels were not different between RF and RF-GH rats. Food intake of RF and PFS rats was 64% of ALS intake and was associated with poor gains in weight and length by the PFS and RF groups (relative weight and length gains were ALS>PFS>RF,P<0.05 for all comparisons); this suggests that the poor growth of RF rats when compared with PFS rats was due to factors other, than food intake. Serum IGF-I levels of 771±249 ng/ml in PFS rats were lower than levels of 1109±253 ng/ml found in the ALS group (P<0.05); this is consistent with the malnourished state of PFS rats. Serum IGF-I levels in RF rats (950±236 ng/ml) were not different from ALS or PFS levels despite the fact that RF rats gained less weight and length than either the ALS or PFS rats. We conclude that RF rats increase in length, use ingested calories more efficiently, and fail to develop marked insulin resistance when treated with met-hGH. We find that, in addition to poor food intake, other factors contribute to growth failure in this model of renal failure. Finally, we find that RF rats have normal levels of IGF-I, suggesting that low IGF-I levels are not a major cause of growth failure in rats with renal failure. 相似文献
20.
目的 研究重组人生长激素对肝纤维化发生和发展过程的影响。方法 应用尾静脉攻击注射人血白蛋白方法诱导大鼠形成免疫损伤性肝纤维化模型。基础免疫后,在尾静脉攻击注射白蛋白即肝纤维化模型形成的过程中,同时给予外源性的重组人生长激素来干预肝纤维化的发生和发展。攻击注射10周后,观察肝组织病理肝纤维化分级;测定肝组织胆原蛋白含量;检测血清层粘连蛋白和透明质酸的含量和肝功能指标。结果 重组人生长激素能够减轻肝组织病理肝纤维化分级(P<0.01);降低胶原蛋白、层粘连蛋白和透明质酸的含量(P<0.05);同时改善肝功能(P<0.05)。结论 重组人生长激素能够阻断或延缓大鼠免疫损伤性肝纤维化的发生和发展,具有一定程度的抗肝纤维化的作用。 相似文献